Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 23.00p 82,454 05:00:01
Bid Price Offer Price High Price Low Price Open Price
22.00p 24.00p 23.00p 23.00p 23.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 25.40 -10.88 -10.56 16.2

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:01:2223.70704166.85O
13:24:3322.002,500550.00O
13:04:0522.007,5001,650.00O
12:25:4922.104,000884.00O
12:06:2023.702,000474.00O
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

DateSubject
15/11/2018
08:20
Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 23p.
Summit Corporation has a 4 week average price of 21p and a 12 week average price of 21p.
The 1 year high share price is 242.50p while the 1 year low share price is currently 21p.
There are currently 70,260,991 shares in issue and the average daily traded volume is 100,942 shares. The market capitalisation of Summit Corporation is £16,160,027.93.
20/9/2018
11:35
football: So basically the share price covers money in the bank and the funding we have already lined up and all the drugs we have in the pipeline for free going by market?
04/8/2018
17:52
the canadian mounted: Kirk6 is correct in thinking this price is achievable.current valuation of cash assets is not reflective of the company products currently in the pipeline. One failure does not deserve a 80% drop in share price,a re rating imo will occur soon.
03/8/2018
16:41
b1tcoin: Riseup what am I suppose to do when MMS spike the share price quickly? Do you knowwhy they spike shares price? They entice sellers so they can smash the share price Look when spread was 52p-55p. Are you saying, I should keep my stance when I know exactly what they doing? Shall I keep my stance when I know their objective with quick spike was to trash the price. Yes I believe 100% and yes also saw their motivation with that spike. what's wrong posting I took off? It was 65% up. it went up 20% to 65% within mins. it was a b1tcoin rally right. I never said I would wait for 100% to sell and clearly had to re-adjust my forecast due to the spike I have never you seen posting here, I have been here for a month or so. b1tcoin3 Aug '18 - 07:45 - 24075 of 24113 Edit 0 0 0 Nice rns
30/7/2018
08:20
football: Hyper Al the link was a bit tongue in cheek and a very tenuous link to summit but does go to show the depths of project fear, I would of fought this movement of people would contain infectious diseases not the other way around. Anyway let's hope all director buys recently and the company focusing on this disease now news can't be far away along with a much-needed share price rise or rerating from here. Good luck
27/6/2018
13:46
chrisatrdg: I feel the same way waterloo01 takes me back to the meeting we all had at which Summit had to raise more capital & the share price halved but this is worse.This is Antisoma all over again we were warned.I just cannot understand why at 24 wks all looked so good just need to match it at 48 wks & here we are pulling the plug.Something wrong ?
08/6/2018
08:18
wildbunch: HM. Don't lets carried away by the comparison. Just a £125k swing overnight makes one think about risk/reward! I also chatted with execs after the AGM. Of course a £200m offer would be resisted. However, Sarepta has both cash and paper and potentially a strategic imperative to own Summits DMD portfolio sooner rather than later. There are a number of price inflection points looming. Should we get the results the execs are clearly anticipating then the share price must rise-then more so each time more news-approach to regulators for fast track-approval granted-launch-sales numbers etc. It would make sense for Sarepta to come in as soon as they think they could strike a deal-this could be in the £500m to £1bn range-personally I would not want that if the July results are good.
21/5/2018
12:27
luminoso: Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment. Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT. At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?
01/5/2018
16:29
luminoso: Strengthening dollar has offset recent fall on nasdaq and prevented it being translated to AIM in the form of a few pence off our price. The inertia of the SUMM price works both ways and will only really react to quite dramatic moves in SMMT over on nasdaq, I guess.
27/3/2018
07:28
football: Suppose I'm like most here clicked on the newsfeed and you see another big placing and think FFS not again! But then you look at the price of the placing and it's only 4-5p below the bid price which isn't that bad at all. As Hyper Al says it looks like someone wanted in pretty quick and maybe before any drug results hit the market, this placing would have taken a few days so the price probably was about £1.80 when agreed so they probably paid the full price to get in quick rather than spreading it over a couple weeks and maybe forcing the price up higher and costing them more or any positive test results which would of made the share price a lot higher. gla Summit Therapeutics launches placing to raise £15mln to advance its treatment for Duchenne Muscular Dystrophy 07:40 27 Mar 2018 The company said it expects to use the placing’s net proceeds to accelerate preparatory activities for a placebo-controlled clinical trial for DMD treatment ezutromid Read more http://www.proactiveinvestors.co.uk/companies/news/193847/summit-therapeutics-launches-placing-to-raise-15mln-to-advance-its-treatment-for-duchenne-muscular-dystrophy-193847.html
09/2/2018
14:21
hugus maximus: filmster .... well done, I should have sold some but was waiting for a NASDAQ share price hike that didn't materialise. Share price drop has deepened over past few days as the dollar / pound rate moved against us .... uk shares are dollar led ... aside from overall 4% drop in Biotech this week as a result of general share drift. There is nothing to suggest any negative news about the progress of either DMD P2 or C Diff at Summit.
Summit Corp share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20181115 15:43:57